A prospective, real‑world, multinational study of febrile neutropenia (FN) occurrence in oncology patients receiving chemotherapy with intermediate risk of FN : a MASCC neutropenia, infection, and myelosuppression study group initiative
Loading...
Date
Authors
Rapoport, Bernardo Leon
Garcia‑Morillo, Marcial
Font, Carme
Samoon, Zarka
Jabbar, Adnan Abdul
Kourie, Hampig Raphael
Kayumba, Aline
Esposito, Francis
Popescu, Razvan Andrei
Garcia‑Gomez, Jesus
Journal Title
Journal ISSN
Volume Title
Publisher
Springer
Abstract
PURPOSE : Limited knowledge is available on the incidence of febrile neutropenia (FN) in intermediate-risk patients and the rationale for use of granulocyte colony-stimulating factor (G-CSF) in these patients. We aimed to estimate the rate at which patients associated with intermediate risk (10–20%) of FN would develop ≥ 1 episode of FN with a commonly used chemotherapy regimen in clinical practice. METHODS : This prospective, real-world, observational, multinational, multicenter study (December 2016–October 2019) recruited patients with solid tumors or Hodgkin’s/non-Hodgkin’s lymphoma. Patients receiving chemotherapy with intermediate risk of FN, but not G-CSF as primary prophylaxis were included and observed for the duration of the chemotherapy (≤ 6 cycles and ≤ 30 days after the last chemotherapy administration). RESULTS : In total, 364 patients (median age, 56 years) with 1601 cycles of chemotherapy were included in the analysis. The incidence of FN was 5% in cycle 1, 3% in cycles 2–3, and 1% in cycles 4–6. The rate of patients with ≥ 1 episode of FN was 9%, and 59% of FN events were reported during cycle 1. The rate of grade 4 neutropenia in cycle 1 was 11%, and 15% of patients experienced ≥ 1 episode of grade 4 neutropenia. CONCLUSIONS : Overall, the incidence of FN was low, with a high incidence in cycle 1 and a decrease in the subsequent cycles. These results provide the real FN risk for common chemotherapy regimens in patients generally excluded from clinical trials. Prophylactic G-CSF in intermediate-risk patients could be considered as per clinician’s judgement.
Description
DATA AVAILABILITY : Novartis supports the publication of scientifically rigorous analysis that is relevant to patient care, regardless of a positive or negative outcome. Qualified external researchers can request access to anonymized patient-level data, respecting patient-informed consent, through www. clini calst udyda tareq uest. com, according to requirements noted on the web portal.
Keywords
Chemotherapy, Neutropenia, Febrile neutropenia, Risk, SDG-03: Good health and well-being
Sustainable Development Goals
SDG-03:Good heatlh and well-being
Citation
Rapoport, B.L., Garcia-Morillo, M., Font, C. et al. 2023, 'A prospective, real‑world, multinational study of febrile neutropenia (FN) occurrence in oncology patients receiving chemotherapy with intermediate risk of FN : a MASCC neutropenia, infection, and myelosuppression study group initiative', Supportive Care in Cancervol. 31, no. 628, pp. 1-8. https://doi.org/10.1007/s00520-023-08071-0.